Improved in vitro quality of stored red blood cells upon oxygen reduction prior to riboflavin/UV light treatment of whole blood.

Peter Schubert, Brankica Culibrk, Deborah Chen, Katherine Serrano, Elena Levin, Zhongming Chen, Peter Zoescher, Raymond P Goodrich, Tatsuro Yoshida, Dana V Devine

Journal: Transfusion 2020;59(10):3197-3204

PMID: 31408208

Abstract

BACKGROUND

The application of riboflavin/UV-based pathogen inactivation (PI) to whole blood (WB) is currently limited by its negative impact on red blood cell (RBC) quality. The generation of reactive oxidative species in RBC products contributes to increased hemolysis. This study evaluated the impact of deoxygenation of WB prior to riboflavin/UV light treatment versus deoxygenation of RBC concentrates after PI treatment by monitoring RBC in vitro quality parameters.

STUDY DESIGN AND METHODS

Six ABO-matched WB units were pooled and split. Within three pairs, one unit was treated with riboflavin/UV light while the other was kept as an untreated control prior to manufacture into red cell concentrates (RCCs). The first pair (Cntr; Cntr-PI) served as the normoxic controls. Deoxygenation was performed at the RCC level for the second pair (RCCdeox; PI-RCCdeox), and at the WB level of the third pair (WBdeox; WBdeox-PI). In vitro qualities of the respective RBC units were assessed throughout storage.

RESULTS

The data for the Cntr and Cntr-PI units were comparable to previous reports. The PI-RCCdeox units exhibited worse in vitro quality for most parameters tested compared to Cntr-PI and WBdeox-PI units throughout storage. Hemolysis and microvesicle release was significantly (p < 0.05) higher on Days 21 and 42 in Cntr-PI units compared to WBdeox-PI units.

CONCLUSION

WB deoxygenation may help to decrease the accelerated deterioration in RCC in vitro quality caused by treatment with riboflavin/UV light. Treatment of WB under reduced oxygen levels needs to be assessed for PI effectiveness.

© 2019 AABB.

Address: Centre for Innovation, Canadian Blood Services, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Innovation, Canadian Blood Services, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Infectious Disease Research Center at Colorado State University, Fort Collins, Colorado.; Hemanext, Lexington, Massachusetts.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.